We are live on ! Find out more
AKYA

Akoya BioSciences
AKYA

Delisted

AKYA was delisted on the 7th of July, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in Akoya BioSciences in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

25.1% less ownership

Funds ownership: 25.1% → 0% (-25%)

100% less funds holding

Funds holding: 58 → 0 (-58)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $16.3M → $0 (-$16.3M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 58

Holders
–
Holders Change
-58
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
58
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BWLSA
Blue Water Life Science Advisors
California
-$6.11M
2
OBAM
ODDO BHF Asset Management
France
-$2.46M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$1.55M
4
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Texas
-$872K
5
TC
Trium Capital
United Kingdom
-$787K
Name Holding Trade Value Shares
Change 		Change in
Stake
BWLSA
1
Blue Water Life Science Advisors
California
– -$6.11M -4,697,785 Closed
OBAM
2
ODDO BHF Asset Management
France
– -$2.46M -1,892,855 Closed
Vanguard Group
3
Vanguard Group
Pennsylvania
– -$1.55M -1,194,127 Closed
PAPAIJV
4
Paragon Associates & Paragon Associates II Joint Venture
Texas
– -$872K -671,000 Closed
TC
5
Trium Capital
United Kingdom
– -$787K -605,496 Closed
BlackRock
6
BlackRock
New York
– -$649K -499,510 Closed
Geode Capital Management
7
Geode Capital Management
Massachusetts
– -$319K -245,665 Closed
PCA
8
Peddock Capital Advisors
Massachusetts
– -$305K -234,720 Closed
ECM
9
ExodusPoint Capital Management
New York
– -$267K -205,320 Closed
Jane Street
10
Jane Street
New York
– -$233K -179,381 Closed
State Street
11
State Street
Massachusetts
– -$231K -177,447 Closed
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
– -$230K -176,961 Closed
Goldman Sachs
13
Goldman Sachs
New York
– -$225K -173,441 Closed
UBS Group
14
UBS Group
Switzerland
– -$225K -173,132 Closed
CIEC
15
Crédit Industriel et Commercial
France
– -$221K -170,000 Closed
JP Morgan Chase
16
JP Morgan Chase
New York
– -$182K -139,973 Closed
JC
17
JBF Capital
Colorado
– -$155K -119,508 Closed
Citadel Advisors
18
Citadel Advisors
Florida
– -$131K -100,467 Closed
CL
19
CSS LLC
Illinois
– -$125K -96,011 Closed
Millennium Management
20
Millennium Management
New York
– -$119K -91,576 Closed
Northern Trust
21
Northern Trust
Illinois
– -$109K -83,490 Closed
Morgan Stanley
22
Morgan Stanley
New York
– -$108K -83,019 Closed
Marshall Wace
23
Marshall Wace
United Kingdom
– -$96K -73,881 Closed
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
– -$88.5K -68,110 Closed
ZIC
25
ZWJ Investment Counsel
Georgia
– -$62.4K -47,975 Closed
1
2 3

AKYA Hedge Fund Activity: Q3 2025 in Review

0 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q3 2025, worth a combined $0 — down 100% from $16.3M a quarter earlier.

Sellers outnumbered buyers: 58 funds closed out of AKYA and 0 opened new positions — a net loss of 58 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Blue Water Life Science Advisors, exiting entirely with an estimated $6.11M sold.

  • 0 institutional investors held Akoya BioSciences (AKYA) as of Q3 2025, down from 58 in Q2 2025.
  • Funds reported $0 of Akoya BioSciences stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Akoya BioSciences positions in Q3 2025 and 58 closed out, a net change of -58 holders.
  • The largest Akoya BioSciences seller in Q3 2025 was Blue Water Life Science Advisors, an estimated $6.11M sold.

Based on aggregated 13F filings for Q3 2025.